Normal-tension glaucoma patients with low night-time through diastolic blood pressure (DBP) are at heightened risk of visual field progression, and this risk is associated with the duration and magnitude of nocturnal DBP dip, a study has found.
Greater physical activity, such as increased walking and more time spent doing moderate-to-vigorous or nonsedentary activity, may reduce visual field (VF) loss in a treated population of patients with glaucoma, a study has found. Moreover, adding 5,000 daily steps or 2.6 hours of nonsedentary physical activity decreases the average rate of VF by 10 percent.
Use of intravitreal antivascular endothelial growth factor (anti-VEGF) therapy in patients with diabetic macular oedema (DME) in routine clinical practice does not escalate the hazard of cerebrovascular disease, myocardial infarction or major bleeding within 6 months after treatment, reports a study.
Treatment with water-free cyclosporine formulation at either 0.1% or 0.05% concentration is tolerable and provides effective relief of the signs of dry eye disease, according to data from a phase II study.
A decade after ophthalmologists adopted the use of electronic health records (EHRs), providers have been found to spend more time using EHR for an office visit, generate longer notes and close the chart faster, according to a study. Such changes may increase time and documentation pressure for providers.
A recent study suggests the use of Mohs micrographic surgery (MMS) for eyelid sebaceous carcinoma (SC) without orbital involvement to help prevent its recurrence. However, MMS has not succeeded in changing the long-term outcomes regarding metastasis or tumour-related mortality.
Patients with neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend protocol and who have tolerated some subretinal fluid (SRF) appear to achieve visual acuity (VA) outcomes similar to that of treatment aimed at resolving all SRF, according to a study.
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.